Plus Launches National Upfit Program Delivering Class 8 Semi-Autonomous Trucks Within a Day
9.5.2022 15:00:00 EEST | Business Wire | Press release
Plus, a global provider of self-driving truck technology, announced today that it has selected Velociti, a global leader in fleet technology solutions, as the deployment and maintenance partner for the national Plus Build program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510005059/en/
Plus Build (Graphic: Business Wire)
The Plus Build program takes less than a day to turn new and existing Class 8 freight trucks into semi-autonomous trucks by equipping them with state-of-the-art lidar, radar, and camera sensors and Plus’s proprietary autonomous driving software. The result is PlusDrive, the industry’s first commercially available autonomous trucking solution. PlusDrive improves safety, enhances driver comfort, and saves at least 10% in fuel costs. Installation is performed at locations most convenient to customers, in or near major transportation hubs across the U.S. Maintenance services are available nationwide by utilizing mobile resources to meet customers where they are.
Shawn Kerrigan, COO and Co-founder of Plus, said: “Plus Build helps companies unlock the benefits of autonomous driving technology today by quickly modernizing trucks to improve their safety and uptime. Velociti’s unmatched technology installation and service network will help us get PlusDrive into the hands of more truck drivers across the country to make their jobs safer, easier, and better.”
Through the Plus Build program and partnership with Velociti, Plus is now deploying PlusDrive nationwide. Some of the world’s largest fleets and truck manufacturers are already participating in Plus Build and are operating PlusDrive-enabled trucks on the road today. In addition to Velociti’s technology installation services, Plus is implementing Velociti’s VeloCare solution, a flagship proactive system-health monitoring program including remote and mobile services to maximize technology uptime.
“Partnering with Plus to provide our services as an important part of the PlusDrive solution leverages Velociti’s decades of experience deploying and maintaining innovative fleet technologies. We are excited to enter into this strategic partnership to help PlusDrive customers realize the benefits this transformational technology brings to their businesses and to the transportation industry,” said Ryan Powell, Senior Vice President at Velociti.
Supervised by a truck operator, PlusDrive can autonomously handle the following in normal traffic conditions on a highway:
- Lane centering
- Driver initiated lane change
- Traffic jam assist
- Predictive fuel optimization
- Adaptive cruise control (down to zero)
- Lane merging
- Driver attentiveness detection
- Operational Design Domain (ODD) checker
- Self-calibration
- Over-the-air updates
For more information on the Plus Build program or PlusDrive, please contact sales@plus.ai.
About Plus
Plus is a global leader in the autonomous trucking revolution, with award-winning high-performance full-stack driverless technology. Named by Fast Company as one of the World’s Most Innovative Companies of 2022, Plus is the only autonomous driving company with customers operating its product on the road today. Working with one of the largest companies in the U.S., vehicle manufacturers and others, Plus is making long-haul trucking safer, more fuel efficient, more sustainable, and more comfortable for the drivers. Plus has received a number of industry awards and distinctions for its transformative technology and business momentum from Fast Company, Insider, Consumer Electronics Show, AUVSI, and others.
For more information, please visit www.plus.ai or follow us on LinkedIn or YouTube.
About Velociti
Velociti, a global provider of enterprise technology solutions for more than 25 years, helps meet complex business needs by optimizing technology investments, lowering costs, and improving employee and customer experience. Its innovative design, rapid installation and deployment, and proactive support services for a broad range of transportation and networking technologies are provided by a highly experienced team of engineers, project managers, certified technicians and customer success representatives. Velociti serves enterprises in transportation and logistics, construction, retail, food service, manufacturing, distribution, government, and hospitality including many Fortune 500 companies.
For more information visit http://www.velociti.com or call toll free (855)-233-7210.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005059/en/
Contact information
PLUS
Lauren Kwan
pr@plus.ai
VELOCITI
Megan Blevins
megan.blevins@velociti.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom